THE PROTECT STUDY: EFFECT OF 35 MONTH EVEROLIMUS MONOTHERAPY VS. CALCINEURIN INHIBITOR-BASED THERAPY ON EFFICACY AND RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS

被引：0
|
作者：
Schlitt, H. [1 ]
Kaiser, G. [2 ]
Richter, N. [3 ]
Heyne, N. [4 ]
Rauchfuss, F. [5 ]
Pascher, A. [6 ]
Schemmer, P. [7 ]
Fischer, L. [8 ]
Paulus, E. [9 ]
Mertens, M. [9 ]
Sterneck, M. [8 ]
机构：
[1] Univ Hosp Regensburg, Dept Surg, Regensburg, Germany
[2] Univ Hosp Essen, Dept Gen Visceral & Transplantat Surg, Essen, Germany
[3] Hannover Med Sch MHH, Clin Gen Abdominal & Transplant Surg, Hannover, Germany
[4] Univ Tubingen Hosp, Dept Gen Visceral & Transplant Surg, Tubingen, Germany
[5] Jena Univ Hosp, Dept Gen Abdominal & Vasc Surg, Jena, Germany
[6] Charite Univ Med Ctr Berlin, Clin Gen Abdominal & Transplant Surg, Berlin, Germany
[7] Univ Heidelberg Hosp, Dept Gen Visceral & Transplant Surg, Heidelberg, Germany
[8] Univ Med Ctr Eppendorf, Dept Gen Surg & Transplantat, Hamburg, Germany
[9] Novartis Pharma GmbH, Nurnberg, Germany
来源：
TRANSPLANT INTERNATIONAL | 2013年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [1] THE PROTECT STUDY: EVEROLIMUS MONOTHERAPY vs. CALCINEURIN INHIBITOR-BASED THERAPY RESULTS IN PROGRESSIVE RENAL FUNCTION BENEFIT OVER 35 MONTHS IN LIVER TRANSPLANT RECIPIENTS
    Sterneck, M.
    Kaiser, G.
    Richter, N.
    Heyne, N.
    Rauchfuss, F.
    Neuhaus, P.
    Schemmer, P.
    Fischer, L.
    Paulus, E. M.
    Mertens, M.
    Schlitt, H. J.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S82 - S82
  • [2] The PROTECT Study: 35 Months of Everolimus Monotherapy vs. Calcineurin Inhibitor-Based Therapy Showed To Be a Safe Alternative with Superior Renal Function in Liver Transplant Recipients.
    Schlitt, H.
    Kaiser, G.
    Richter, N.
    Heyne, N.
    Rauchfuss, F.
    Neuhaus, P.
    Schemmer, P.
    Fischer, L.
    Paulus, E.
    Mertens, M.
    Sterneck, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 130 - 130
  • [3] The PROTECT Study: Everolimus Monotherapy vs. Calcineurin Inhibitor-Based Therapy over 35 Months Showed To Be a Safe Alternative with Superior Renal Function in Liver Transplant Recipients.
    Schlitt, H. J.
    Kaiser, G.
    Richter, N.
    Heyne, N.
    Rauchfuss, F.
    Schemmee, P.
    Fischer, L.
    Paulus, E. -M.
    Mertens, M.
    Sterneck, M.
    [J]. LIVER TRANSPLANTATION, 2013, 19 : S88 - S88
  • [4] The PROTECT study: Renal function benefit with everolimus versus calcineurin inhibitor-based therapy was maintained over 35 months in liver transplant recipients
    Schlitt, Hans J.
    Kaiser, Gernot M.
    Richter, Nicolas
    Heyne, Nils
    Rauchfuss, Falk
    Neuhaus, Peter
    Schemmer, Peter
    Fischer, Lutz
    Paulus, Eva-Maria
    Mertens, Michael
    Sterneck, Martina
    [J]. HEPATOLOGY, 2012, 56 (06) : 1531 - 1532
  • [5] Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: Effect on renal function and proteinuria
    Morales, J.
    Fierro, A.
    Benavente, D.
    Zehnder, C.
    Ferrario, M.
    Contreras, L.
    Herzog, C.
    Buckel, E.
    [J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (03) : 591 - 593
  • [6] Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients
    Budde, K.
    Zeier, M.
    Haller, H.
    Arns, W.
    Kramer, S.
    Vogel, E. M.
    Pietruck, F.
    Reinke, P.
    Rath, T.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 504 - 504
  • [7] Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in De Novo Liver Transplant Recipients Preserves Renal Function
    Montalti, Roberto
    Rompianesi, Gianluca
    Di Benedetto, Fabrizio
    Codeluppi, Mauro
    Cautero, Nicola
    Guerrini, Gian Piero
    Smerieri, Nazareno
    Serra, Valentina
    Iemmolo, Rosa Maria
    Marino, Maria
    De Pietri, Lesley
    Gerunda, Giorgio Enrico
    [J]. LIVER TRANSPLANTATION, 2010, 16 (06) : S134 - S134
  • [8] Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function
    Masetti, M.
    Montalti, R.
    Rompianesi, G.
    Codeluppi, M.
    Gerring, R.
    Romano, A.
    Begliomini, B.
    Di Benedetto, F.
    Gerunda, G. E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (10) : 2252 - 2262
  • [9] Improvement of Renal Function After the Switch from a Calcineurin Inhibitor to Everolimus in Liver Transplant Recipients with Chronic Renal Dysfunction
    Castroagudin, Javier F.
    Molina, Esther
    Romero, Rafael
    Otero, Esteban
    Tome, Santiago
    Varo, Evaristo
    [J]. LIVER TRANSPLANTATION, 2009, 15 (12) : 1792 - 1797
  • [10] Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study.
    Silva, H. Tedesco
    Citterio, F.
    Henry, M.
    Srinivas, T. R.
    Watarai, Y.
    Steinberg, S.
    Basic-Jukic, N.
    Garcia, V. D.
    Mor, E.
    Peddi, V. R.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Pascual, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 358 - 359
12345